Interactions between Ashwaganda and Papaverine
1 drug interaction and 4 additional warnings found for the following 2 drugs:
- ashwaganda
- papaverine
Drug interactions
Minor drug interactions
Minor:
papaverine ashwagandha
Applies to: papaverine and ashwaganda
Ashwagandha has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents or agents with hypotensive properties. There have been no reports of clinical hypotension associated with concomitant use of ashwagandha and antihypertensive agents.
References (2)
- (2024) "Product Information. Ashwagandha (ashwagandha)." Now Foods, 1
- National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Office of Dietary Supplements Ashwagandha https://www.nccih.nih.gov/health/ashwagandha
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
papaverine Food/Lifestyle
Applies to: papaverine
Adjust dosing interval
Smoking before administration of an intracavernosal papaverine/phentolamine combination may reduce its erection-inducing effect.
Management
Smoking should be avoided for at least 1 hour before the intracavernosal papaverine/phentolamine combination is administered. The applicable manufacturer's labeling should be consulted for additional guidance.
References (1)
- (2023) "Product Information. Androskat (papaverine-phentolamine)." Imported (Netherlands)
Moderate:
papaverine Alcohol (Ethanol)
Applies to: papaverine
Monitor
Certain psychotherapeutic and other CNS-active agents may have blood pressure-lowering effects and may cause dizziness, orthostatic hypotension, or syncope. These effects may be more likely during treatment initiation, dose escalation, or treatment restart. Coadministration with antihypertensives or other agents with blood pressure-lowering properties, particularly vasodilators and alpha-adrenergic blockers, may result in additive hypotensive or orthostatic effects.
Management
Monitor blood pressure and clinical response during concomitant use, especially when starting or increasing the dose of either agent. Patients should be advised to rise slowly from a sitting or lying position and to report dizziness, lightheadedness, fainting, orthostasis, palpitations, or troublesome changes in pulse or heart rate. Patients should be cautioned that alcohol may enhance blood pressure-lowering effects during concomitant use with antihypertensives or other agents with hypotensive properties. Patients should avoid driving or operating hazardous machinery until they know how the medications affect them.
References (13)
- Sternbach H (1991) "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol, 11, p. 390-1
- Shook TL, Kirshenbaum JM, Hundley RF, Shorey JM, Lamas GA (1984) "Ethanol intoxication complicating intravenous nitroglycerin therapy." Ann Intern Med, 101, p. 498-9
- Feder R (1991) "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry, 52, p. 139
- Ellison JM, Milofsky JE, Ely E (1990) "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry, 51, p. 385-6
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. (2001) "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit, 23, p. 435-40
- Pacher P, Kecskemeti V (2004) "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des, 10, p. 2463-75
- Andrews C, Pinner G (1998) "Postural hypotension induced by paroxetine." BMJ, 316, p. 595
- (2023) "Product Information. Buprenorphine (buprenorphine)." G.L. Pharma UK Ltd
- (2023) "Product Information. Temgesic (buprenorphine)." Reckitt Benckiser Pty Ltd
- (2026) "Product Information. Urapidil (Carinopharm) (urapidil)." Imported (EU)
- (2020) "Product Information. URAPIDIL ACCORD (urapidil)." ACCORD HEALTHCARE LIMITED
- (2020) "Product Information. Ebrantil (urapidil)." CHEPLAPHARM ARZNEIMITTEL GMBH
- (2026) "Product Information. Urapidil (urapidil)." Imported (Switzerland)
Disease interactions
2 potential interactions Applies to: 2 conditions, including Glaucoma/Intraocular Hypertension and Heart Block.
Glaucoma/Intraocular Hypertension
Moderate:
papaverine
Papaverine has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
The use of papaverine derivatives has been associated with an increase in intraocular pressure. Therapy with papaverine derivatives should be administered cautiously in patients with glaucoma.
Heart Block
Major:
papaverine
Papaverine has a major potential interaction with Heart Block.
The use of papaverine and papaverine derivatives is contraindicated in patients with complete AV heart block. When conduction is depressed, these agents can induce transient ectopic rhythms of ventricular origin, either premature beats or paroxysmal tachycardia. Therapy with these agents should be administered cautiously in patients with conduction disturbances, including sinus bradyarrhythmia and partial or first-degree AV block.
More resources
ashwaganda
A total of 486 drugs are known to interact with ashwaganda.
- Ashwaganda is in the drug class herbal products.
- Ashwaganda is used to treat Herbal Supplementation.
papaverine
A total of 398 drugs are known to interact with papaverine.
- Papaverine is in the drug class peripheral vasodilators.
- Papaverine is used to treat Vasospasm.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.